English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The objective of this study was to investigate the  in vivo  activity of the lantibiotic lacticin 3147 against the luminescent  Staphylococcus aureus  strain Xen 29 using a murine model. Female BALB/c mice (7 weeks old, 17 g) were divided into groups ( n  = 5) and infected with the Xen 29 strain via the intraperitoneal route at a dose of 1 × 10 6  cfu/animal. After 1.5 hr, the animals were treated subcutaneously with doses of phosphate-buffered saline (PBS; negative control) or lacticin 3147. Luminescent imaging was carried 3 and 5 hours postinfection. Mice were then sacrificed, and the levels of  S. aureus  Xen 29 in the liver, spleen, and kidneys were quantified. Notably, photoluminescence and culture-based analysis both revealed that lacticin 3147 successfully controlled the systemic spread of  S. aureus  in mice thus indicating that lacticin 3147 has potential as a chemotherapeutic agent for  in vivo  applications.

The Lantibiotic Lacticin 3147 Prevents Systemic Spread ofStaphylococcus aureusin a Murine Infection Model